Ranolazine for the Prevention of Atrial Fibrillation After Electrical Cardioversion
Status:
Terminated
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that ranolazine would decrease the incidence of recurrence of
Atrial Fibrillation (AF) after electrical cardioversion of persistent AF. Patients with
persistent AF who are candidates for electrical cardioversion will be randomized to either
placebo or ranolazine after successful electrical cardioversion.